Literature references Sample Clauses

The 'Literature references' clause defines how references to external literature, such as books, articles, or scientific papers, are to be cited and used within the agreement or document. Typically, this clause specifies the required citation format, the scope of acceptable sources, and may outline how updates or changes to referenced materials are handled. Its core function is to ensure consistency, accuracy, and clarity in referencing external works, thereby reducing ambiguity and supporting the reliability of the information cited in the document.
Literature references. For addi- tional background information on this test guideline, the following references should be consulted:
View SourceView Similar (10)
Literature references. F o r a ddi- t io n a l b a c k g r o un d i nfo r m a t io n o n t h i s t es t g u ideli n e, t h e followi n g r efe r e n ces s h o u ld be co n s u l t ed:
View SourceView Similar (3)
Literature references. 2 Emos G. et al., Efficacy and safety of AEZS-108 (INN: Doxorubicin Acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: A multicenter Phase II trial of the ago- study group (AGO GYN 5), Gynecol Oncol 2014 Jun, 133 (3): 427-32 3 Emons G, ▇▇▇▇▇ S, ▇▇▇▇▇▇ P, ▇▇▇▇▇▇▇ J, Wimberger P, ▇▇▇▇▇▇▇ A, ▇▇▇▇▇▇ ▇▇, ▇▇▇▇▇▇▇ F, ▇▇▇▇ P, Gruendker C, AGO Study Group. Phase II study of AEZS-108 (AN-152), a targeted cytotoxic LHRH analog, in patients with LHRH receptor- positive platinum resistant ovarian cancer. J Clin Oncol 2010 ASCO Annual Meeting Proceedings;28(15s):abstract 5035.
View SourceView Similar (2)
Literature references. 1 ▇▇▇▇▇▇▇▇▇ ▇▇, ▇▇▇▇▇▇▇ AV, ▇▇▇▇▇ M, ▇▇▇▇ AM, ▇▇▇▇ A, ▇▇▇▇▇▇▇▇▇▇ K, ▇▇▇▇▇▇▇▇▇ A Targeting of doxorubicin to ES-2 human ovarian cancers in nude mice by linking to an analog of luteinizing hormone-releasing hormone improves its effectivenessInt. J. Oncology 2001; 19:571-7
View Source
Literature references. 1. ▇▇▇▇▇▇▇▇▇ ▇▇, ▇▇▇▇▇▇▇▇ I, ▇▇▇▇▇ ▇▇, ▇▇▇ M, ▇▇▇▇▇▇ CC, ▇▇▇▇▇▇▇▇▇ N. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database of Systematic Reviews 2014: Issue 1. Art. No.: CD009593. 2. Systematic screening for active tuberculosis. Principles and recommendations. WHO/HTM/TB/2013.04 (▇▇▇▇://▇▇▇.▇▇▇.▇▇▇/tb/publications/Final_TB_Screening_guidelines.pdf) 3. Kivihya-Ndugga LEA, Van Cleeff MRA, Githui WA, ▇▇▇▇▇▇ ▇▇, Kibuga DK, ▇▇▇▇▇▇▇▇ ▇▇, ▇▇▇▇▇▇▇ ▇▇. A comprehensive comparison of ▇▇▇▇▇-▇▇▇▇▇▇▇ and fluorescence microscopy for the diagnosis of tuberculosis in a resource-poor urban setting. Int J Tuberc Lung Dis. 2003: 7(12):1163–1171. PMID:14677891. 4. ▇▇▇▇▇▇▇ ▇▇, ▇▇▇▇▇▇ ▇ ▇, ▇▇▇▇▇▇ A, ▇▇▇▇▇▇▇ E, ▇▇▇▇▇▇▇▇ F, ▇▇▇▇▇▇ K, ▇▇▇▇ T, ▇▇▇▇▇▇ C, ▇▇▇▇▇▇▇ R, ▇▇▇▇▇▇▇ ▇▇, ▇▇▇▇▇▇ ▇▇. Impact of human immunodeficiency virus type-1 infection on the initial bacteriologic and radiographic manifestations of pulmonary tuberculosis in Uganda. Int J Tuberc Lung Dis. 1998: 2(5) 397-404. PMID: 9613636. 5. ▇▇▇▇▇▇▇ T, ▇▇▇▇▇▇▇▇ ▇, ▇▇▇▇▇▇▇ Y, ▇▇▇▇▇▇ Y, ▇▇▇▇▇ ▇. Two-Thirds of Smear-Positive Tuberculosis Cases in the Community Were Undiagnosed in Northwest Ethiopia: Population Based Cross-Sectional Study. PLoS ONE. 2011: 6(12): e28258. doi:10.1371/journal.pone.0028258.
View Source

Related to Literature references

  • Literature Review A-E shall conduct a literature review to determine which species have been identified as special status by state, federal, and local resources agencies and organizations, and have a potential to occur on the project site or in the immediate vicinity. Sources to be reviewed include: (1) special status species lists from the California Department of Fish and Game (CDFG), United States Fish and Wildlife Service (USFWS), and California Native Plant Society (CNPS); (2) database searches of the California Natural Diversity Database (CNDDB) and the Electronic Inventory of the CNPS; (3) the most recent Federal Register listing package and critical habitat determination for each federally Endangered or Threatened species potentially occurring on the project site; (4) the CDFG Annual Report on the status of California’s listed Threatened and Endangered plants and animals; and (5) other biological studies conducted in the vicinity of the project site.

  • Tariff References 3.5.1 References to state tariffs throughout this Agreement shall be to the currently effective tariff for the state or jurisdiction in which the services were provisioned; provided however, where certain AT&T-21STATE services or tariff provisions have been or become deregulated or detariffed, any reference in this Agreement to a detariffed or deregulated service or provision of such tariff shall be deemed to refer to the service description, price list or other agreement pursuant to which AT&T-21STATE provides such services as a result of detariffing or deregulation. 3.5.2 Wherever the term “customer” is used in connection with AT&T-21STATE’s retail tariffs, the term “customer” means the ultimate consumer or the End User of any tariffed service. 3.5.3 No reference to tariffs in this Agreement shall be interpreted or construed as permitting CLEC to purchase Interconnection Services, under such tariff. Except where expressly permitted elsewhere in this Agreement, notwithstanding the availability of Interconnection Services under tariffs in some AT&T-21STATE incumbent ILEC states, CLEC agrees that any purchase of Interconnection Services addressed by this Agreement or required to be offered by AT&T-21STATE under Section 251 of the Act, shall be purchased solely pursuant to the terms, condition and rates set forth in this Agreement. To the extent that complete terms, conditions and/or rates for any Interconnection Service are not contained in this Agreement at the time CLEC seeks to order such services, the Parties shall amend this Agreement to include such terms, conditions and rates prior to CLEC submitting such order. The rates for Interconnection Services inadvertently or improperly ordered prior to an agreement of the Parties on terms, conditions and/or rates is addressed in the Pricing Schedule.

  • Literature The manufacturer/dealer shall furnish price lists, catalogs, and description literature upon request by any using entity, and at no cost to the entity.

  • Time References Unless otherwise indicated herein, all references to time of day refer to Eastern Standard Time or Eastern daylight saving time, as in effect in New York City on such day. For purposes of the computation of a period of time from a specified date to a later specified date, the word “from” means “from and including” and the words “to” and “until” each means “to but excluding”; provided, however, that with respect to a computation of fees or interest payable to any Secured Party, such period shall in any event consist of at least one full day.

  • Prospectuses and Marketing Materials We shall furnish you without charge reasonable quantities of offering Prospectuses (including any supplements currently in effect), current shareholder reports of the Funds, and sales materials issued by us from time to time. In the purchase of shares through us, you are entitled to rely only on the information contained in the offering Prospectus(es). You may not publish any advertisement or distribute sales literature or other written material to the public that makes reference to us or any of the Funds (except material that we furnished to you) without our prior written approval.